Research Analysts’ Upgrades for June, 25th (ALRN, AMSC, ARCT, ARGX, ASBFY, ATNI, ATRC, AUPH, AUTL, AVXL)

Share on StockTwits

Research Analysts’ upgrades for Tuesday, June 25th:

Aileron Therapeutics (NASDAQ:ALRN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $1.00 price target on the stock. According to Zacks, “Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts. “

American Superconductor (NASDAQ:AMSC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “American Superconductor Corporation is a leading energy technologies company. The company develops and sells a wide range of products and solutions based on power electronic systems and high temperature superconductor wires that dramatically improve the efficiency, reliability and quality of electricity during its generation, transmission, distribution and use. The company is a dominant force in alternative energy, offering grid interconnection solutions as well as licensed wind energy designs and electrical systems. As the world’s principal supplier of HTS wire, AMSC is enabling a new generation of compact, high-power electrical products, including power cables, grid-level surge protectors, motors, generators, and advanced transportation and defense systems. AMSC also provides utility and industrial customers worldwide with voltage regulation systems that dramatically enhance power grid capacity, reliability and security, as well as industrial productivity. “

Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

argenx (NASDAQ:ARGX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $156.00 target price on the stock. According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

ASSD BRIT FOODS/ADR (OTCMKTS:ASBFY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $34.00 target price on the stock. According to Zacks, “Associated British Foods is a diversified international food, ingredients and retail group. The group is one of Europe’s largest food companies with a wide range of successful brands and products in the food sector, and an increasingly strong presence in advanced research and technology. “

ATN International (NASDAQ:ATNI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ATN International, Inc. invests, own and operate communications companies and renewable energy assets. The company through its operating subsidiaries provide wireless and wireline connectivity to residential and business customers including mobile wireless solutions, local exchange services and broadband internet services; distributed solar electric power to corporate, utility and municipal customers and owner and operator of terrestrial and submarine fiber optic transport systems primarily in the United States and the Caribbean. ATN International Inc., formerly known as Atlantic Tele-Network, Inc., is based in Beverly, United States. “

AtriCure (NASDAQ:ATRC) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $35.00 target price on the stock. According to Zacks, “AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart. “

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $7.00 price target on the stock. According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company’s pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. “

Anavex Life Sciences (NASDAQ:AVXL) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company’s proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. “

Brandywine Realty Trust (NYSE:BDN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $17.00 price target on the stock. According to Zacks, “Brandywine Realty Trust is a self-administered, self-managed and fully integrated Real Estate Investment Trust active in acquiring, developing, redeveloping, leasing and managing suburban office and industrial properties. The company’s portfolio includes approximately 151 office properties and 28 industrial facilities. Certain of the Properties serve as flex facilities, accommodating office use, warehouse space and research and development activities. “

BANKINTER S A/S (OTCMKTS:BKNIY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $7.50 price target on the stock. According to Zacks, “Bankinter is in the financial services industry. They are a banking entity subject to the supervision of the Bank of Spain and the Spanish National Securities Market Commission. Their products range from: Current Accounts, Term Deposits, Investment Funds, Pension Plans, Model Portfolios,Insurance Credit and Debit Cards, Assets (Mortgage and pledged loans) and Deposits of Securities. “

Bloomin’ Brands (NASDAQ:BLMN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $21.00 price target on the stock. According to Zacks, “Bloomin’ Brands, Inc. is a casual dining restaurant company with a portfolio of differentiated restaurant concepts. It has five concepts: Outback Steakhouse, Carrabba’s Italian Grill, Bonefish Grill, Fleming’s Prime Steakhouse and Wine Bar and Roy’s. The Company offers its products and services through company owned and franchised locations throughout the United States and internationally. Bloomin’ Brands, Inc. is based in Tampa, Florida. “

SALVATORE FERRA/ADR (OTCMKTS:SFRGY) was upgraded by analysts at Jefferies Financial Group Inc from an underperform rating to a hold rating.

Receive News & Ratings for Aileron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Evercore ISI Initiates Coverage on Arista Networks
Evercore ISI Initiates Coverage on Arista Networks
Credit Suisse Group Upgrades Alcoa  to Outperform
Credit Suisse Group Upgrades Alcoa to Outperform
Norsk Hydro ASA  Upgraded by Goldman Sachs Group to “Buy”
Norsk Hydro ASA Upgraded by Goldman Sachs Group to “Buy”
Peel Hunt Reiterates “Hold” Rating for Mitie Group
Peel Hunt Reiterates “Hold” Rating for Mitie Group
HSBC Reiterates GBX 2,500 Price Target for Royal Dutch Shell
HSBC Reiterates GBX 2,500 Price Target for Royal Dutch Shell
BT Group – CLASS A  Given Sell Rating at Deutsche Bank
BT Group – CLASS A Given Sell Rating at Deutsche Bank


 
© 2006-2019 Zolmax.